The arrival of generic Ozempic (semaglutide) in Canada, following Novo Nordisk’s failure to pay patent fees, is a signal of where the global healthcare and drug pricing landscape is headed.
While exclusivity continues in the United States and Europe until the early 2030s, what makes this moment significant is that it offers the world a real-time “test case” of how generic competition may reshape one of the most profitable drug categories of the decade.
For Novo Nordisk, this represents the beginning of a transition from market dominance to market competition. For generic manufacturers, it is the pregame before much larger markets open.
Companies such as Sandoz and Apotex now have an opportunity to build manufacturing capacity, regulatory familiarity, and distribution networks ahead of eventual patent expiries in the U.S. and EU.
The timing is equally important. Key markets, including China, India, and Brazil, are approaching expiry windows and have started preparing large-scale market entries that could significantly expand access to GLP-1 therapies worldwide.
In several markets, monthly treatment costs could eventually fall to $15 to $30 in some countries, compared with hundreds of dollars for the brand-name version. If this occurs, what was once a premium therapy may soon become widely accessible for diabetes and obesity management.
There is also a geopolitical dimension. Canada’s lower-cost environment could recreate familiar cross-border dynamics, similar to insulin purchasing patterns seen in the past, in which patients from high-priced jurisdictions look outward for affordable treatment.
In many ways, this is less about one drug and more about the future of pharmaceutical economics. Canada is now running a live experiment on how innovation, patents, pricing power, and public health priorities intersect when blockbuster medicines move from exclusivity to accessibility.
The results of this experiment will likely shape global drug policy conversations for the next decade.
#Ozempic #Semaglutide #GLP1 #Obesity #FatLossDrugs #NovoNordisk #Canada #India #Patent #Diabetes #CurareLegal #Healthcare
https://lnkd.in/g62i5v6D
